AUPM864894A0 - Treatment of bowel-dependent neurological disorders - Google Patents

Treatment of bowel-dependent neurological disorders

Info

Publication number
AUPM864894A0
AUPM864894A0 AUPM8648A AUPM864894A AUPM864894A0 AU PM864894 A0 AUPM864894 A0 AU PM864894A0 AU PM8648 A AUPM8648 A AU PM8648A AU PM864894 A AUPM864894 A AU PM864894A AU PM864894 A0 AUPM864894 A0 AU PM864894A0
Authority
AU
Australia
Prior art keywords
bowel
treatment
neurological disorders
dependent neurological
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPM8648A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BORODY TJ
Original Assignee
BORODY TJ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BORODY TJ filed Critical BORODY TJ
Priority to AUPM8648A priority Critical patent/AUPM864894A0/en
Publication of AUPM864894A0 publication Critical patent/AUPM864894A0/en
Priority to NZ293542A priority patent/NZ293542A/en
Priority to PCT/AU1995/000664 priority patent/WO1996011014A1/en
Priority to AU36014/95A priority patent/AU706968B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPM8648A 1994-10-07 1994-10-07 Treatment of bowel-dependent neurological disorders Abandoned AUPM864894A0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AUPM8648A AUPM864894A0 (en) 1994-10-07 1994-10-07 Treatment of bowel-dependent neurological disorders
NZ293542A NZ293542A (en) 1994-10-07 1995-10-06 Treatment of bowel microflora to relive neurological disorders
PCT/AU1995/000664 WO1996011014A1 (en) 1994-10-07 1995-10-06 Treatment of bowel-dependent neurological disorders
AU36014/95A AU706968B2 (en) 1994-10-07 1995-10-06 Treatment of bowel-dependent neurological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM8648A AUPM864894A0 (en) 1994-10-07 1994-10-07 Treatment of bowel-dependent neurological disorders

Publications (1)

Publication Number Publication Date
AUPM864894A0 true AUPM864894A0 (en) 1994-11-03

Family

ID=3783167

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPM8648A Abandoned AUPM864894A0 (en) 1994-10-07 1994-10-07 Treatment of bowel-dependent neurological disorders

Country Status (3)

Country Link
AU (1) AUPM864894A0 (en)
NZ (1) NZ293542A (en)
WO (1) WO1996011014A1 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE507696C2 (en) * 1996-03-20 1998-07-06 Lars Wiklund Use of a physiologically harmless ammonium compound and / or urea for the prophylaxis of sudden infant death and ways of diagnosing the risk of sudden infant death
DK0951289T3 (en) * 1996-12-18 2006-03-13 Stanford Rook Ltd Use of Mycobacterium vaccae for the treatment of chronic fatigue syndrome
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
SE9604844D0 (en) * 1996-12-30 1996-12-30 Carl Gerhard Gottfries Agents for the therapeutic treatment of fibromyalgia and chronic fatigue syndrome
EP0986314B1 (en) * 1997-06-03 2008-09-10 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with sids
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6444203B2 (en) 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
FR2808689B1 (en) * 2000-05-11 2004-09-03 Agronomique Inst Nat Rech USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
AU2008293896B2 (en) 2007-08-29 2014-10-02 Ganeden Biotech, Inc. Baked goods
AU2008317000B2 (en) 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
ES2595733T3 (en) 2008-10-16 2017-01-03 Ganeden Biotech, Inc. Probiotic cereal-based compositions
AU2014221272B2 (en) * 2008-11-03 2016-01-21 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
BRPI0921617A2 (en) * 2008-11-03 2015-08-18 Nestec Sa Nutritional composition comprising probiotics and improved sleep patterns
US8568743B2 (en) 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
DK3564357T3 (en) 2010-02-01 2022-06-20 Rebiotix Inc BACTERIA THERAPY AGAINST CLOSTRIDIUM DIFFICILE COLITIS
WO2011151941A1 (en) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition having activity of inducing proliferation or accumulation of regulatory t cell
KR20130098320A (en) 2010-08-04 2013-09-04 토마스 줄리어스 보로디 Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
JP5931884B2 (en) * 2010-10-07 2016-06-08 カリフォルニア インスティチュート オブ テクノロジー Live bacteria therapy for autism
MX355760B (en) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them.
EP2683390B1 (en) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
DK2877163T3 (en) 2012-07-27 2019-04-15 Redhill Biopharma Ltd FORMULATIONS AND PROCEDURES FOR THE PREPARATION OF FORMS FOR USING GAS DRAINAGE
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP4234011A3 (en) 2013-06-05 2023-09-20 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CA2966363A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (en) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
KR102523805B1 (en) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 Immune modulation
EP3294307A4 (en) 2015-05-14 2019-01-23 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
AU2016274757B2 (en) 2015-06-09 2019-02-07 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PT3240554T (en) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
PT3307288T (en) 2015-06-15 2019-10-17 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
DK3206700T3 (en) 2015-06-15 2019-08-05 4D Pharma Res Ltd COMPOSITIONS COMPREHENSIVE BAKERY STUES
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
KR101914245B1 (en) 2015-11-20 2018-11-02 4디 파마 리서치 리미티드 Composition Containing Bacterial Strain
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA42560B1 (en) 2016-03-04 2019-07-31 4D Pharma Plc Compositions comprising bacterial strains of blautia for the treatment of visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US11707493B2 (en) 2016-05-23 2023-07-25 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018250206A1 (en) 2017-04-05 2019-10-31 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (PD) and related disorders
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
TW201907928A (en) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 a composition comprising a bacterial strain
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
ES2841902T3 (en) 2017-06-14 2021-07-12 4D Pharma Res Ltd Compositions comprising bacterial strains
MA49425A (en) 2017-06-14 2020-04-22 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
WO2019087841A1 (en) * 2017-11-01 2019-05-09 ビオフェルミン製薬株式会社 AGENT FOR PREVENTING OR TREATING SMALL INTESTINAL DISORDER INDUCED BY CERTAIN NSAIDs AND PPI
JPWO2019087842A1 (en) * 2017-11-01 2020-11-12 ビオフェルミン製薬株式会社 Non-steroidal anti-inflammatory drugs and proton pump inhibitors Prophylactic or therapeutic agents for induced small bowel disorders
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640349B2 (en) * 1988-08-02 1993-08-26 Borody, Thomas J Dr Treatment of gastro-intestinal disorders

Also Published As

Publication number Publication date
NZ293542A (en) 2000-12-22
WO1996011014A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU3056297A (en) Techniques of treating neurodegenerative disorders by brain infusion
PL339425A1 (en) Treatment of behavioural disorders
AU1173195A (en) Treatment of immunoregulatory disorders
IL141263A0 (en) Methods for treatment of neurological disorders
EP0729361A4 (en) Method of treating neurological disorders
AU2972497A (en) Treatment of oils
AUPO274596A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
AU3977700A (en) Method of treating neurological disorders
AU2058697A (en) Treatment of sleep disorders
AU4131296A (en) Treatment of disorders with duloxetine
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU4704797A (en) Use of benzopyranols to treat neurological disorders
AUPM456894A0 (en) Treatment for gastric disorders
AU5518694A (en) Treatment of a group of related disorders
GB9518887D0 (en) Treatment of muscular disorders
AU1926597A (en) Treatment of cocoa
AU1282099A (en) Method for treatment of disorders of attention
AUPO504297A0 (en) Treatment of neurological disorders
AU5503090A (en) Imidazodiazepines for the treatment of neurological symptons
AU2245695A (en) Composition for treating neurological disorders
AUPM424794A0 (en) Treatment of anorectal disorders